Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

AstraZeneca Stock Sees Relative Strength Rating Rise To 85

AstraZeneca ADR sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Widow of BBC presenter who died after Covid jab says ‘no alternative’ but to sue AstraZeneca

BBC Radio Newcastle’s Lisa Shaw had her first jab in May 2021 and died just a week later

The Independent UK

Widow of BBC presenter who died after Covid jab says ‘no alternative’ but to sue AstraZeneca

BBC Radio Newcastle’s Lisa Shaw had her first jab in May 2021 and died just a week later

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Climate emergency is the biggest health crisis of our time – bigger than Covid

As toll on public health and global economy rises, radical action is needed on greenhouse gas emissions

The Guardian - UK

Husband of BBC journalist Lisa Shaw to sue AstraZeneca after her death

BBC presenter and beloved mum Lisa Shaw died from complications following her jab in 2021

Liverpool Echo

Husband of BBC presenter Lisa Shaw to sue AstraZeneca after her death from Covid vaccine complications

AstraZeneca said that its vaccines have 'clear and stringent standards to ensure' their safety

Manchester Evening News

BBC presenter's husband taking legal action after death from rare Covid jab complications

The husband of BBC presenter Lisa Shaw, who died at the age of 44 from rare complications following her first Covid jab, is part of a group of claimants who have lost relatives

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

As Space Traffic Increases, Rockets Pose a Growing Risk to Airplanes

Planes risk serious damage from rocket debris, but politicians can pressure space organizations to take action.

Inverse

'I have 'Jolie gene' and petrified my cancer will return - new NHS drug gives me future'

Claire Spragg was diagnosed with triple negative breast cancer and discovered she carried the faulty BRCA2 gene. She was able to take a year's supply of olaparib, which is now available on the NHS

Daily Mirror

Husband of North East radio presenter who died after AstraZeneca Covid-19 vaccine taking legal action

Lisa Shaw, 44, who worked for BBC Radio Newcastle, died a week after her first jab

Chronicle Live

Cancer patients to receive ‘life-changing’ AstraZeneca drug through NHS

Clinical trials have shown the drug could extend advanced prostate cancer patients’ lives by an average of six months, NHS England said

The Independent UK

Medical Behemoth AstraZeneca Flirts With Breakout On Fresh Hope In Ovarian Cancer

AstraZeneca said Wednesday a combination of its drugs Lynparza and Imfinzi met the goal of a key study, leading AZN stock to surge.

Investors Business Daily

Airplanes face a growing risk of being hit by uncontrolled re-entries of rockets used to launch satellites

On May 11, 2020 a deadly threat flew from Los Angeles to New York City in under nine minutes. It was a 20-tonne Chinese Long March 5B rocket body passing around 60 miles overhead.

The Conversation

Jeremy Hunt aims to spur business investment with ‘full expensing’ tax break

Measure over next three years will allow firms to write off costs of IT equipment and machinery against tax on profits

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Daily Mirror

Thousands still waiting for Covid jab payout as over £5million paid in damages so far

Under the Vaccine Damage Payment Scheme, those harmed by the coronavirus jab get a £120,000 payment but thousands are still waiting for their claims to be assessed

Investors Business Daily

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

StockNews.com

The Best Stock to Buy for Under $100 Right Now

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

Investors Business Daily

AstraZeneca's Trading Range Makes This Options Trade Appealing

AztraZeneca (AZN), a U.K. developer of branded prescription therapeutics, ranks first in IBD's diversified medical industry group. But the Composite Rating is only 63. This, combined with the weakening of the market, makes this a solid choice for our familiar short iron condor. With the suspicion that the markets are…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Rishi Sunak faces Tory Budget rebellion over corporation tax REDIRECTED

Leaders of Tory several factions write to PM urging rethink

Daily Mirror

Kwasi Kwarteng STILL supports 'general direction' of his economy-destroying mini budget

Former Chancellor of the Exchequer Kwasi Kwarteng is sticking by the "general direction" of his mini budget that crashed the UK economy, but admits that he has regrets

The Guardian - UK

RMT strikes to continue, says Mick Lynch, after members reject ‘dreadful’ pay offers – as it happened

RMT general secretary says members could not accept offer he says would make railways less safe

The Guardian - UK

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

Investors Business Daily

AstraZeneca Hits Its Stride On Upbeat Guidance With 'Desirable' Growth

AstraZeneca's earnings topped forecasts Thursday, but sales came in light. AZN stock rose on its upbeat 2023 guidance.

Investors Business Daily

Dow Jones Rallies 250 Points After Jobless Claims; Disney Surges On Earnings

The Dow Jones rallied 250 points Thursday after weekly first-time jobless claims. Disney shares surged on earnings results.

Evening Standard

End of vaccine boost for AstraZeneca as it looks elsewhere for growth

The firm made just shy of $4 billion from sales of its Covid-19 vaccine in 2021, but sales have since more than halved and were down 95% at the tail end of last year

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.